Jakavi 5mg Tablet

Jakavi 5mg Tablet contains the active ingredient Ruxolitinib and belongs to the class of kinase inhibitors. It is an advanced anticancer medication used to treat myelofibrosis, a rare bone marrow cancer that disrupts normal blood cell production. It is also prescribed for polycythemia vera, a condition where the body produces too many red blood cells, particularly in patients who do not respond well to hydroxyurea. Additionally, Jakavi 5mg tablet for GVHD (Graft versus Host Disease) is approved for adults and children aged 12 and above who have not responded adequately to steroid or systemic therapies. The Jakavi 5mg for myelofibrosis dosage is determined by the physician based on body weight, blood counts, and treatment response. It works by blocking abnormal signalling pathways that drive excessive cell growth, helping to reduce symptoms like spleen enlargement and fatigue. Patients should avoid this medication if allergic to Ruxolitinib or any of its components. Inform your doctor beforehand if you have a history of tuberculosis, hepatitis B or C, liver or kidney disease, or low blood cell counts. Common side effects include dizziness, headache, swelling, bruising, and reduced platelet levels. Notify your doctor immediately if you experience persistent bleeding or infection. For affordability, the Jakavi 5mg Tablet price and Ruxolitinib 5mg tablet price in India may vary by pharmacy or region. Patients can buy Jakavi 5mg Tablet online from trusted sources to ensure authenticity. The Novartis Jakavi 5mg price reflects its high-quality manufacturing standards. If unavailable, your doctor may suggest a Jakavi 5mg substitute such as Ruxolix, though Jakavi 5mg vs Ruxolix 5mg comparisons show both have similar efficacy and composition. Eligible patients can also explore the Jakavi 5mg Patient Assistance Program, which provides financial support to make treatment more accessible. Overall, Jakavi remains a trusted option in modern haematology for managing complex blood and bone marrow disorders.